4700 Spring Street
121 articles with Regen BioPharma
Regen BioPharma, Inc. has received a number of inquiries regarding a potential reverse merger with another biotechnology related company.
Regen BioPharma, Inc. Examines Combining Cannabidiol (CBD) With Its Lead NR2F6 Agonist To Treat for Inflammatory Bowel Disease
Regen BioPharma, Inc., reports its researchers have determined that combining its lead NR2F6 small molecule agonist with Cannabidiol (CBD) may provide a dynamic therapy for treating inflammatory bowel disease (IBD)
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) researchers have identified three new series of small molecule drugs that inhibit NR2F6, bringing the total number of these series to five.
Regen BioPharma, Inc. Determines Its Lead NR2F6 Agonist Ready for Inflammatory Bowel Disease Animal Studies
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that its lead NR2F6 small molecule agonist, RG-NAH005, is now ready for testing in animal models of inflammatory bowel disease (IBD)
Regen BioPharma Inc. reports its researchers have identified a series of small molecule drugs that inhibit NR2F6 and also activate human immune cells ex-vivo.
No Toxicity Seen in Mice as Regen BioPharma, Inc. Finishes Initial Optimization of its Lead NR2F6 Small Molecule Agonist
Regen BioPharma Inc.'s lead candidate drug, RG-NAE005, was tested for its maximum tolerated dose in mice and showed no signs of toxicity.
Company is preparing for efficacy experiments in mice.
Regen BioPharma's Medicinal Chemistry Program Has Identified Additional Compounds That Activate NR2F6
Regen BioPharma (OTCQB: RGBP) and (OTCQB: RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6.
Regen BioPharma Files Additional Composition of Matter Patent Application on NR2F6-Modulating Small Molecules
Regen BioPharma today announced filing a patent application covering composition of matter and methods of use related to molecules identified in its small molecule program that activate and inhibit NR2F6.
Regen BioPharma has initiated in vivo and ex vivo assessments to determine the effects of some of the Company's NR2F6 small molecule agonists in live rats and in tissues derived from humans and rats.
Regen BioPharma Chairman Discusses the Rationale for Pursuing Autoimmune Indications by Activating the Nuclear Receptor NR2F6
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, one can unleash the cancer-killing potential of a patient's own immune system.
Regen BioPharma's Chief Scientific Officer Explains the Link Between its NR2F6 Medicinal Chemistry and Three-Dimensional X-Ray Structure Programs
The company recently began a program to determine the three-dimensional structure of the NR2F6 nuclear receptor.
Regen BioPharma Announces Former Eli Lilly Executive and Current CVS Board Member will Lead Newly Formed Business Advisory Board
Regen BioPharma announced that former Eli Lilly executive Jean-Pierre Millon will serve as chairman of its newly formed business advisory board.
Regen BioPharma and (OTCQB: RGBPP) has begun a program to determine the 3-dimensional structure of NR2F6 both with and without the Company's proprietary small molecule drugs bound to it.
Regen BioPharma Researchers Capitalize on Key Structure in Compounds that Activate Checkpoint NR2F6 for the Potential Treatment of Autoimmune Diseases
Regen BioPharma and (OTCQB: RGBPP) believes it has taken full advantage of its recent prior discovery in developing small molecule drugs that activate NR2F6.
Regen BioPharma Researchers Demonstrate Direct Binding Of Proprietary Agonists To Immune Checkpoint NR2F6
Regen BioPharma Addresses Potential Impact of Recent Bristol-Myers Squibb's $2.3 Billion Acquisition Of IFM Therapeutics
Regen BioPharma Addresses Potential Impact Of Recent Bristol-Myers Squibb $2.3 Billion Acquisition Of IFM Therapeutics